Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04188288 · ClinicalTrials.gov registry record · NA
Neurofeedback in Individuals With Substance Use Disorders
A NA study, sponsored by Yale University.
- Terminated
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT04188288: Clinical Trial NA study, sponsored by Yale University.
NCT04188288 is a NA study that was terminated before completion, run by Yale University. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04188288, a NA study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
The aim of this study is to train individuals with opioid use disorder to control their brain activity in a way that has been associated with their symptoms. Participants in the experimental group will be given direct feedback regarding their brain activity while they are undergoing functional magnetic resonance imaging (fMRI) scanning, and will try to learn to control their brain activity during these feedback sessions. A separate group of participants will be given a control form of feedback that we do not believe can have clinical benefits. Our primary hypothesis is that the neurofeedback training will reduce opioid use and clinical features of opioid use disorder more than the control feedback.
Primary Outcome
Opioid use will be monitored by weekly urine test. This will be assessed as the percentage of negative tests.
Interventions
- DEVICE fMRI
- DEVICE Experimental feedback
- DEVICE Control feedback
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2023-03-15 |
| Phase | NA |
Why NCT04188288 stopped before completion
NCT04188288 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which fMRI is the first listed.
NCT04188288 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04188288 about?
NCT04188288 is a clinical study titled "Neurofeedback in Individuals With Substance Use Disorders". The aim of this study is to train individuals with opioid use disorder to control their brain activity in a way that has been associated with their symptoms. Participants in the experimental group will be given direct feedback regarding their brain activity while they are undergoing functional magne...
What is the current status of trial NCT04188288?
This trial is currently terminated. It is a NA study. The enrollment target is 12 participants. The study started on 2021-07-01. Estimated completion is 2023-03-15.
What interventions are being tested in trial NCT04188288?
The interventions under investigation include: fMRI (DEVICE), Experimental feedback (DEVICE), Control feedback (DEVICE).
Who is sponsoring clinical trial NCT04188288?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04188288's enrollment target sits among peer trials
12 1913th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI